How long should I take brigatinib/brigatinib?

The duration of treatment with Brigatinib/Brigatinib (Brigatinib) can vary based on individual differences and disease status. The specific treatment duration should be evaluated and decided by the doctor based on the patient's condition and efficacy. ForALK (anaplastic lymphoma Kinase) fusion-positive non-small cell lung cancer (NSCLC) who are treated with brigatinib/in first-line or second-line treatment, it is generally recommended to continue treatment until disease progression, intolerable side effects, or the patient no longer benefits. In first-line treatment, based on the results of the ALTA-1L study, brigatinib/brigatinib pan>has shown longer progression-free survival (PFS) and overall survival (OS), so it can be used as a first-line treatment option. In this case, patients can continue to receive Brigatinib/Brigatinib treatment according to the doctor’s advice to prolong disease control and survival.